Activity of nab-paclitaxel in a heavily-pretreated breast cancer patient who experienced a change of tumour biology

被引：0

作者：

Pluschnig U. ^{[1
]}

Neumann H.-J. ^{[1
]}

机构：

[1] Department of Internal Medicine, A. Ö. Krankenhaus der Elisabethinen Klagenfurt GmbH, 9020 Klagenfurt am Wörthersee

来源：

memo - Magazine of European Medical Oncology | 2014年 / 7卷 / 2期

关键词：

Breast cancer; Hormone receptor switch; Nab-paclitaxel; Taxane therapy;

D O I：

10.1007/s12254-014-0147-7

中图分类号：

学科分类号：

摘要：

The patient described here was diagnosed with hormone-receptor-positive breast cancer and underwent numerous treatments in the neoadjuvant, adjuvant and palliative settings. Metastatic disease occurred that was confined to the bone, but kept progressing over several years. Due to the short-lasting nature of the patient's responses to various endocrine agents, a re-biopsy was performed and a hormone receptor switch to triple negativity was established. With nab-paclitaxel therapy, disease stabilisation has been achieved for 8 months. The patient has tolerated this therapy very well in spite of massive pretreatment. © 2014 Springer-Verlag.

引用

页码：119 / 121

页数：2

共 14 条

[1]

Hoefnagel L.D., Van Der Groep P., Van De Vijver M.J., Et al., Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient, Ann Oncol, 24, pp. 3017-3023, (2013)

[2]

Gelderblom H., Verweij J., Nooter K., Sparreboom A., Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation, European Journal of Cancer, 37, 13, pp. 1590-1598, (2001)

[3]

Lorenz W., Reimann H.J., Schmal A., Histamine release in dogs by Cremophor E1 and its derivatives: Oxethylated oleic acid is the most effective constituent, Agents and Actions, 7, 1, pp. 63-67, (1977)

[4]

Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker Jr. J.R., Van Echo D., Von Hoff D.D., Leyland-Jones B., Hypersensitivity reactions from taxol, Journal of Clinical Oncology, 8, 7, pp. 1263-1268, (1990)

[5]

Ten T.A.J., Verweij J., Loos W.J., Sparreboom A., Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy, Clinical Pharmacokinetics, 42, 7, pp. 665-685, (2003)

[6]

Sparreboom A., Van Zuylen L., Brouwer E., Loos W.J., De Bruijn P., Gelderblom H., Pillay M., Nooter K., Stoter G., Verweij J., Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications, Cancer Research, 59, 7, pp. 1454-1457, (1999)

[7]

Winer E.P., Berry D.A., Woolf S., Duggan D., Kornblith A., Harris L.N., Michaelson R.A., Kirshner J.A., Fleming G.F., Perry M.C., Graham M.L., Sharp S.A., Keresztes R., Henderson I.C., Hudis C., Muss H., Norton L., Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342, Journal of Clinical Oncology, 22, 11, pp. 2061-2068, (2004)

[8]

Van Tellingen O., Huizing M.T., Nannan P.V.R., Schellens J.H.M., Nooijen W.J., Beijnen J.H., Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients, British Journal of Cancer, 81, 2, pp. 330-335, (1999)

[9]

Motamed K., SPARC (osteonectin/BM40), Int J Biochem Cell Biol, 31, pp. 1363-1366, (1999)

[10]

Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J., Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer, Journal of Clinical Oncology, 23, 31, pp. 7794-7803, (2005)

← 1 2 →